Clinical Report: Efficacy and Safety of Dipyridamole in Kawasaki Disease

Overview

This meta-analysis evaluates the efficacy and safety of dipyridamole combined with immunoglobulin and aspirin for treating Kawasaki disease in children. Results indicate a higher effective rate and improved clinical outcomes in the observation group compared to the control group.

Background

Kawasaki disease (KD) is a serious pediatric vasculitis that can lead to significant coronary artery damage if not treated promptly. Current treatment typically involves high-dose intravenous immunoglobulin and aspirin, but some patients exhibit resistance to these therapies. The addition of dipyridamole may offer enhanced therapeutic benefits for these patients.

Data Highlights

Key Findings

• The total effective rate was significantly higher in the observation group receiving dipyridamole.
• Clinical symptom improvement occurred more rapidly in the observation group.
• Levels of C-reactive protein, erythrocyte sedimentation rate, and fibrinogen were significantly lower in the observation group.
• Platelet counts and coronary artery lesions were also reduced in the observation group.
• No significant difference in adverse reactions was observed between the two groups.

Clinical Implications

The findings indicate that incorporating dipyridamole into the treatment regimen for Kawasaki disease may enhance clinical outcomes without increasing the risk of adverse effects.

Conclusion

Dipyridamole combined with immunoglobulin and aspirin demonstrates superior efficacy in treating Kawasaki disease in children compared to immunoglobulin and aspirin alone, with a comparable safety profile.

Related Resources & Content

1. Frontiers | Dipyridamole combined with immunoglobulin and aspirin in the treatment of Kawasaki disease in children: a meta-analysis
2. JAMA Network Open — Validation of a 2-Gene Blood Test for Kawasaki Disease in Febrile Children
3. Frontiers in Cardiovascular Medicine — A triad of hypertension, heart failure, and glomerular injury in subacute Kawasaki disease: a case report and literature review
4. Pediatric Cardiology — Infliximab as an Effective Second-Line Treatment for IVIG-Resistant Kawasaki Disease Accompanied by Severe Dyslipidemia
5. Pediatric Cardiology — Evaluation of Risk Assessment Models for Predicting Coronary Artery Dilation in Kawasaki Disease within a North American Population
6. Update on Diagnosis and Management of Kawasaki Disease: A Scientific Statement From the American Heart Association
7. AHA Scientific Statement Update on Kawasaki Disease: Identifying and Managing Patients at High Risk - American College of Cardiology
8. 26-A-16351-ACC THE EFFECTIVENESS OF NO OR LOW-DOSE VERSUS HIGH-DOSE ASPIRIN IN ACUTE KAWASAKI DISEASE: AN UPDATED META-ANALYSIS | JACC
9. Different antithrombotic strategies to prevent cardiovascular complications in Kawasaki patients: a systematic review and meta-analysis | BMC Pediatrics | Springer Nature Link
10. Adjunctive glucocorticoids in Kawasaki disease | Nature Reviews Rheumatology
11. Frontiers | Dipyridamole combined with immunoglobulin and aspirin in the treatment of Kawasaki disease in children: a meta-analysis